BioMarin

YTD

ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307.

CEO

Alexander Hardy

CEOAlexander Hardy

Employees

3,221

Employees3,221

Headquarters

San Rafael, California

HeadquartersSan Rafael, California

Founded

1997

Founded1997

Employees

3,221

Employees3,221

BMRN Key Statistics

Market cap

9.70B

Market cap9.70B

Price-Earnings ratio

36.34

Price-Earnings ratio36.34

Dividend yield

—

Dividend yield—

Average volume

2.13M

Average volume2.13M

High today

$53.04

High today$53.04

Low today

$49.41

Low today$49.41

Open price

$49.78

Open price$49.78

Volume

2.19M

Volume2.19M

52 Week high

$66.28

52 Week high$66.28

52 Week low

$49.26

52 Week low$49.26

Stock Snapshot

With a market cap of 9.7B, BioMarin(BMRN) trades at $51.33. The stock has a price-to-earnings ratio of 36.34.

During the trading session on 2026-05-21, BioMarin(BMRN) shares reached a daily high of $53.04 and a low of $49.41. At a current price of $51.33, the stock is +3.9% higher than the low and still -3.2% under the high.

Trading activity shows a volume of 2.19M, compared to an average daily volume of 2.13M.

The stock's 52-week range extends from a low of $49.26 to a high of $66.28.

BMRN News

TipRanks 13h

Why BioMarin’s Stock Is Sinking Despite Trial Win - TipRanks

...

TipRanks 14h

BioMarin’s Voxzogo meets endpoint in Phase 3 pediatric hypochondroplasia trial

BioMarin (BMRN) Pharmaceutical announced that the Phase 3 CANOPY-HCH-3 study evaluating treatment with Voxzogo – vosoritide – in children with hypochondroplasia...

Simply Wall St 22h

BioMarin Trial Setback Puts Rare Disease Pipeline And Valuation In Focus

BioMarin Pharmaceutical (NasdaqGS:BMRN) reported that BMN 401 missed one of two co-primary endpoints in the Phase 3 ENERGY 3 trial for ENPP1 deficiency. The th...

Analyst ratings

79%

of 29 ratings

Buy

79.3%

Hold

20.7%

Sell

More BMRN News

Nasdaq 2d

BMRN Stock Down on Mixed Results From Rare Disease Therapy Study

Shares of BioMarin Pharmaceutical BMRN were down 4% on Monday after it reported results from the phase III ENERGY 3 study, which evaluated BMN 401, an investiga...

TipRanks 2d

BioMarin price target lowered to $80 from $85 at BofA

BofA analyst Jason Zemansky lowered the firm’s price target on BioMarin (BMRN) to $80 from $85 and keeps a Buy rating on the shares after the company announced...

TipRanks 6d

Morgan Stanley Sees the S&P 500 Hitting 8,300 – 2 Stocks It Says Could Surge Alongside It

The earnings season is winding down, and Wall Street has reasons to stay optimistic. Corporate America continues delivering resilient results, with S&P 500 comp...

TipRanks 7d

BioMarin Extends BMN 351 Duchenne Study, Keeping Long-Term Data in Focus for Investors

Biomarin Pharmaceutical Inc. (BMRN) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter,...

People also own

Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.